EZH2, an epigenetic driver of prostate cancer

Yeqing Angela Yang, Jindan Yu*

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

92 Scopus citations

Abstract

The histone methyltransferase EZH2 has been in the limelight of the field of cancer epigenetics for a decade now since it was first discovered to exhibit an elevated expression in metastatic prostate cancer. It persists to attract much scientific attention due to its important role in the process of cancer development and its potential of being an effective therapeutic target. Thus here we review the dysregulation of EZH2 in prostate cancer, its function, upstream regulators, downstream effectors, and current status of EZH2-targeting approaches. This review therefore provides a comprehensive overview of EZH2 in the context of prostate cancer.

Original languageEnglish (US)
Pages (from-to)331-341
Number of pages11
JournalProtein and Cell
Volume4
Issue number5
DOIs
StatePublished - 2013

Keywords

  • EZH2
  • epigenetics
  • histone methyltransferase
  • prostate cancer

ASJC Scopus subject areas

  • Biotechnology
  • Biochemistry
  • Drug Discovery
  • Cell Biology

Fingerprint Dive into the research topics of 'EZH2, an epigenetic driver of prostate cancer'. Together they form a unique fingerprint.

Cite this